As the FDA increasingly adopts AI-driven risk analysis and advanced compliance monitoring tools to identify high-risk facilities, pharmaceutical and biotech companies must transition from periodic inspection preparation to continuous inspection readiness.
This intensive 2-day virtual seminar provides practical strategies to help organizations prepare for evolving FDA inspection models, data-driven enforcement trends, AI-assisted risk targeting, and increasing regulatory expectations surrounding GMP compliance, data integrity, CAPA effectiveness, and quality culture.
Participants will learn how to strengthen inspection readiness programs, reduce compliance vulnerabilities, and build sustainable systems that support perpetual regulatory readiness.
This intensive 2-day virtual seminar provides practical strategies to help organizations prepare for evolving FDA inspection models, data-driven enforcement trends, AI-assisted risk targeting, and increasing regulatory expectations surrounding GMP compliance, data integrity, CAPA effectiveness, and quality culture.
Participants will learn how to strengthen inspection readiness programs, reduce compliance vulnerabilities, and build sustainable systems that support perpetual regulatory readiness.
Speaker
Kelly ThomasWho Should Attend
- Quality Assurance Professionals
- GMP Compliance Teams
- Manufacturing & Operations Leaders
- Validation & CSV Professionals
- Regulatory Affairs Teams
